Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585158 | 0.85 | NR1H2 (0.45) | NR1H2NR1H3CA12CA9L3MBTL1 | |
| SCHEMBL7016266 | 0.83 | NR1H2 (0.46) | NR1H2NR1H3CA12CA9PARP1 | |
| SCHEMBL20494743 | 0.81 | NR1H2 (0.45) | NR1H2NR1H3CA12CA9CHRM2 | |
| SCHEMBL7484481 | 0.79 | DCTPP1 (0.47) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL133464 | 0.76 | ALDH1A1 (0.57) | NR1H2L3MBTL1BCHE | |
| SCHEMBL6581361 | 0.75 | NR1H2 (0.39) | NR1H2NR1H3CA12CA9BCHE | |
| SCHEMBL16460751 | 0.73 | DCTPP1 (0.36) | NR1H2NR1H3CA12CA9BCHE | |
| SCHEMBL861356 | 0.73 | NR1H2 (0.35) | NR1H2NR1H3CA12CA9BCHE | |
| SCHEMBL7023036 | 0.72 | NR1H2 (0.39) | NR1H2NR1H3CA12CA9CHRM2 | |
| SCHEMBL4715525 | 0.72 | NR1H2 (0.44) | NR1H2NR1H3CA12CA9HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844015-B2 | Pyridine dicarboxamide derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-20190202786-A1 | PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202786-A1 | PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRPF3 | NR1H2 1175/4885NR1H3 1123/4885CA12 2198/4885 |
| US-10844015-B2 | Pyridine dicarboxamide derivatives as bromodomain inhibitors | BRD4, BRD3, BRPF3 | NR1H2 1175/4885NR1H3 1123/4885CA12 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.